AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by 180 Wealth Advisors LLC

180 Wealth Advisors LLC increased its position in AstraZeneca PLC (NASDAQ:AZN) by 4.6% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,291 shares of the company’s stock after acquiring an additional 368 shares during the period. 180 Wealth Advisors LLC’s holdings in AstraZeneca were worth $562,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of AZN. Sanders Capital LLC grew its holdings in AstraZeneca by 39.0% during the 4th quarter. Sanders Capital LLC now owns 14,684,066 shares of the company’s stock valued at $988,972,000 after buying an additional 4,122,965 shares during the last quarter. Norges Bank purchased a new position in shares of AstraZeneca in the 4th quarter worth $143,999,000. Manning & Napier Group LLC raised its position in shares of AstraZeneca by 281.2% in the 4th quarter. Manning & Napier Group LLC now owns 2,779,212 shares of the company’s stock worth $187,180,000 after buying an additional 2,050,064 shares during the period. Clearbridge Investments LLC raised its position in shares of AstraZeneca by 118.9% in the 4th quarter. Clearbridge Investments LLC now owns 3,592,447 shares of the company’s stock worth $241,951,000 after buying an additional 1,951,591 shares during the period. Finally, abrdn plc raised its position in shares of AstraZeneca by 346.3% in the 4th quarter. abrdn plc now owns 1,420,876 shares of the company’s stock worth $95,696,000 after buying an additional 1,102,490 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on AZN shares. Argus raised their price objective on AstraZeneca from $80.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, May 30th. Barclays raised AstraZeneca to a “strong-buy” rating in a research report on Monday. Citigroup raised AstraZeneca to a “strong-buy” rating in a research report on Monday. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, April 16th. Finally, The Goldman Sachs Group started coverage on AstraZeneca in a research report on Thursday, May 30th. They issued a “buy” rating and a $97.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, AstraZeneca has an average rating of “Buy” and a consensus target price of $88.00.

AstraZeneca Stock Performance

AZN stock traded down $0.90 during midday trading on Thursday, reaching $78.18. The company had a trading volume of 2,796,709 shares, compared to its average volume of 5,608,135. The company has a quick ratio of 0.70, a current ratio of 0.89 and a debt-to-equity ratio of 0.73. The stock has a 50 day moving average price of $77.33 and a 200 day moving average price of $70.25. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $80.86. The firm has a market capitalization of $242.40 billion, a PE ratio of 38.32, a P/E/G ratio of 1.43 and a beta of 0.48.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Thursday, April 25th. The company reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.08. The company had revenue of $12.68 billion for the quarter, compared to analysts’ expectations of $11.92 billion. AstraZeneca had a return on equity of 30.42% and a net margin of 13.30%. Analysts anticipate that AstraZeneca PLC will post 4.04 earnings per share for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.